ABBOTT PARK, Ill., Sept. 19, 2025 /PRNewswire/ — The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 59 cents per share. This marks the 407th consecutive quarterly dividend to be […]
Resilience
FDA Grants Orphan Drug Designation to NS-051/NCNP-04 for the Treatment of Duchenne Muscular Dystrophy
PARAMUS, N.J., Sept. 19, 2025 /PRNewswire/ — NS Pharma, Inc. announced today that the U.S. Food & Drug Administration (FDA) has granted Orphan Drug Designation to NS-051/NCNP-04 which is being developed for the treatment of […]
DarwinCell Showcases novel MSC-based drug ALT001 at the 150th American Neurological Association Annual Meeting
BALTIMORE, Sept. 19, 2025 /PRNewswire/ — The 150th American Neurological Association Annual Meeting (ANA 2025) was successfully held in Baltimore, USA, from September 13 to 16, 2025. The conference brought together leading global experts, scholars, and […]
Truelli Advances Breakthrough R&D to Transform the Future of Women's Health
NEW YORK, Sept. 19, 2025 /PRNewswire/ — Truelli, a pioneering healthtech startup, is advancing its research and development on the world’s first menstrual pad with a built-in screening technology designed to transform a period into […]
2025 IMS | IASO Bio Highlights Three-Year Follow-Up Data of CAR-T Cell Therapy Fucaso for Multiple Myeloma Treatment
SHANGHAI, NANJING, China and PLEASANTON, Calif., Sept. 18, 2025 /PRNewswire/ — IASO Biotherapeutics (“IASO Bio”), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies, today announced that the 36-month […]
